Yuan Yuan
Medical Oncology · Pasadena, CANPI 1073664660
Payments from drug & device makers
Across 627 payments — averaging $15,175 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3.8M
- Merck$3.4M
- Daiichi Sankyo Inc.$656K
- AstraZeneca$640K
- Eisai Inc.$242K
- Novartis$176K
- plus $544K from 23 others
Across 10 payments — averaging $1342.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$13K
- F. Hoffmann-la Roche AG$729
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 94 | $3,819,197 |
| Merck | 104 | $3,438,318 |
| Daiichi Sankyo Inc. | 70 | $655,715 |
| AstraZeneca | 112 | $639,767 |
| Eisai Inc. | 42 | $241,635 |
| Novartis | 28 | $176,240 |
| Genentech, Inc. | 7 | $150,732 |
| Gilead | 83 | $135,690 |
| Puma Biotechnology, Inc. | 2 | $73,928 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $67,384 |
| Hoffmann-la Roche Limited | 4 | $49,709 |
| Genentech USA, Inc. | 29 | $33,129 |
| AbbVie | 14 | $13,648 |
| Seagen Inc. | 2 | $4,680 |
| Eli Lilly | 4 | $4,212 |
| Stemline Therapeutics Inc. | 3 | $2,584 |
| Sanofi | 1 | $2,552 |
| Macrogenics, Inc. | 1 | $1,500 |
| Immunomedics, Inc. | 1 | $1,375 |
| Tersera Therapeutics LLC | 1 | $1,078 |
| Bristol Myers Squibb | 1 | $1,000 |
| Athenex Pharmaceutical Division, LLC | 1 | $175 |
| Beigene USA, Inc. | 1 | $141 |
| Amgen | 3 | $136 |
| Biontech SE | 1 | $81 |
| Therakos LLC | 1 | $37 |
| Tempus AI, Inc | 1 | $26 |
| GE HealthCare | 1 | $25 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$9,514,709 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Pasadena
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
- Sandhya SrinivasStanford$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.